CING 4.80 Cingulate Inc.
| Range: | 1.8-152.4 | Vol Avg: | 3890812 | Last Div: | 0 | Changes: | 0.1 |
| Beta: | -0.93 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Dec 08 2021 | Empoloyees: | 13 | ||
| CUSIP: | 17248W105 | CIK: | 0001862150 | ISIN: | US17248W2044 | Country: | US |
| CEO: | Dr. Shane J. Schaffer Pharm.D. | Website: | https://www.cingulate.com | ||||
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow